What are the different pneumococcal vaccines (conjugate vaccines PCV13, PCV15, PCV20 and polysaccharide vaccine PPSV23) and the recommended vaccination schedules for infants, adults, and immunocompromised patients?

Pneumococcal Vaccines: Types and Vaccination Schedules

For adults ≥50 years, a single dose of PCV20 or PCV21 alone is now the preferred and simplest approach, eliminating the need for PPSV23 in most cases. 1, 2

Available Pneumococcal Vaccines

Conjugate Vaccines (PCVs)

• PCV13 (13-valent): Older formulation, largely replaced by higher-valency vaccines
• PCV15 (15-valent): Adds 2 serotypes beyond PCV13; requires PPSV23 follow-up
• PCV20 (20-valent): Adds 7 serotypes beyond PCV13; standalone vaccine
• PCV21 (21-valent): Newest option; standalone vaccine but excludes serotype 4

Polysaccharide Vaccine

• PPSV23 (23-valent): Contains 23 serotypes but generates weaker immune response than conjugate vaccines; now primarily used in series with PCV15 or for specific catch-up scenarios

Key distinction: Conjugate vaccines (PCVs) produce stronger, longer-lasting immunity with immune memory. PPSV23 produces shorter-duration antibody responses without immune memory 3.

---

Adult Vaccination Schedules (≥19 Years)

Healthy Adults ≥50 Years (Updated 2024)

If vaccine-naïve:

• Single dose of PCV20 or PCV21 (preferred—series complete) 1, 2
• Alternative: PCV15 followed by PPSV23 ≥1 year later (≥8 weeks for immunocompromised) 1

If previously received PPSV23 only:

• Give PCV20, PCV21, or PCV15 ≥1 year after last PPSV23 1

If previously received PCV13 only:

• Give PCV20, PCV21, or PPSV23 ≥1 year after PCV13 1

Critical update: As of October 2024, ACIP expanded age-based PCV recommendations from ≥65 years down to ≥50 years, recognizing substantial pneumococcal disease burden in the 50-64 age group 2.

Adults 19-49 Years with Chronic Conditions

Risk conditions include: chronic heart/lung disease, diabetes, alcoholism, chronic liver disease, smoking 1

If vaccine-naïve:

• Single dose of PCV20, PCV21, or PCV15 1
• If PCV15 given, follow with PPSV23 ≥1 year later 1

Immunocompromised Adults, CSF Leak, or Cochlear Implant (Any Age ≥19 Years)

Conditions include: HIV, malignancy, immunosuppressive therapy, asplenia, sickle cell disease, chronic renal failure, solid organ transplant 4, 1

If vaccine-naïve:

• Single dose of PCV20, PCV21, or PCV15 1
• If PCV15 used, give PPSV23 ≥8 weeks later (shorter interval for high-risk) 1

If previously received PCV13 and 1 dose of PPSV23:

• Give PCV20 or PCV21 ≥5 years after last pneumococcal vaccine 1
• If using second PPSV23 dose instead: give ≥8 weeks after PCV13 AND ≥5 years after first PPSV23 1

Critical timing: For immunocompromised patients, vaccines should be administered before starting immunosuppressive therapy or at diagnosis when possible 5, 6.

Special Consideration: PCV13-Vaccinated Adults

For adults ≥65 years who completed both PCV13 and PPSV23 series:

• Shared clinical decision-making regarding supplemental PCV20 or PCV21 dose 1
• If given, administer ≥5 years after last pneumococcal vaccine 1

This reflects that PCV13 no longer routinely recommended for all adults ≥65 years as of 2019 due to minimal population-level impact from herd immunity 4.

---

Infants and Children

Routine Infant Schedule

• PCV20 or PCV15 now incorporated into routine schedules (PCV13 no longer distributed in US) 7
• Standard 4-dose series: 2,4,6, and 12-15 months 7

High-Risk Children

• May require additional PCV doses or PPSV23 depending on specific risk factors 8
• Conditions include: immunocompromising conditions, asplenia, cochlear implants, CSF leaks 8

Important: PPSV23 no longer routinely recommended for all high-risk children; reserved for specific circumstances 7.

---

Key Clinical Pearls

Vaccine Selection Algorithm

1. PCV20 or PCV21 preferred for simplicity (one-and-done approach) 1
2. Exception: In populations where ≥30% of pneumococcal disease is serotype 4, use PCV20 or PCV15+PPSV23 instead of PCV21 (which lacks serotype 4) 1
3. PCV15 option: Only if planning PPSV23 follow-up; otherwise use higher-valency PCV 1

Timing Intervals

Standard intervals:

• PCV followed by PPSV23: ≥1 year 1
• Between any pneumococcal vaccines: ≥1 year (general) 1

Shortened intervals for high-risk:

• PCV15 to PPSV23: ≥8 weeks (immunocompromised, CSF leak, cochlear implant) 1
• PCV13 to PPSV23: ≥8 weeks (same high-risk groups) 1

Revaccination with PPSV23:

• If first PPSV23 given <65 years: give second dose at ≥65 years, ≥5 years after first dose 4
• No additional PPSV23 doses after dose given at ≥65 years 4

Common Pitfalls

1. Don't coadminister PCV and PPSV23 on same day—always separate 4
2. Don't give PPSV23 before PCV in vaccine-naïve patients—PCV must come first for optimal immune response 4
3. Don't forget catch-up: Adults who received only PPSV23 should still get PCV for better protection 1
4. Immunocompromised patients: Use 8-week interval (not 1-year) between PCV15 and PPSV23 1

Coadministration

Pneumococcal vaccines can be given simultaneously with other age-appropriate vaccines (including influenza, COVID-19) at different injection sites 1.

---

Global Perspective

Many European countries and other nations now preferentially recommend PCV20 as first-line for adults ≥50-65 years and at-risk populations, moving away from complex sequential schedules 5. This reflects the practical advantage of single-dose regimens and broader serotype coverage.